Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + pomalidomide + low-dose dexamethasone versus pomalidomide + low-dose dexamethasone in relapsed/refractory multiple myeloma
2016-003097-41Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of isatuximab in multiple myeloma (MM) (2 arms), sponsored by Sanofi. Primary endpoint: Progression Free Survival. Started Dec 2016; status: completed.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2016-003097-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003097-41.